Improving Community Cancer Care: Progress on All Fronts for SCINTIX Therapy

Meaningful progress across reimbursement, clinical adoption, and product innovation is helping freestanding cancer centers (FSCs) bring SCINTIX^® autonomous radiotherapy to patients in their local communities. This momentum reflects the dedication of our partners in freestanding centers and hospital outpatient departments who are committed to expanding access to advanced cancer care close to home.

Payer Progress: Establishing Fair Medicare Reimbursement

A significant barrier to community-based adoption has been addressed with the recent establishment of Medicare payment rates for SCINTIX procedures in freestanding cancer centers by two Medicare Administrative Contractors (MACs). Novitas Solutions and First Coast Service Options—together covering approximately 30% of the United States—implemented these rates effective January 1, 2026.

Covered geographies include:

• 12 states: Arkansas, Colorado, Delaware, Florida, Louisiana, Maryland, Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania, and Texas

• Additional jurisdictions: District of Columbia, Puerto Rico, U.S. Virgin Islands, Indian Health Service, and the Veterans Health Administration

Approximately 40% of U.S. cancer patients receive radiation therapy in freestanding cancer centers, which are often located closer to where patients live. Historically, these smaller, often physician-owned centers have faced financial challenges when adopting breakthrough technologies. The establishment of these payment rates helps level the playing field, enabling more FSCs to offer SCINTIX as a locally available treatment option.

The reimbursement structure adopted by these MACs includes:

• SCINTIX Delivery (G0563): A uniform technical payment of $3,750.50 across all covered jurisdictions

• SCINTIX Modeling (G0562):

• Technical Component: $1,319 – $1,815.58 (geographically adjusted)

• Professional Component: $392.86 – $460.79 (geographically adjusted)

The professional component recognizes the additional physician expertise required to plan and deliver this novel form of autonomous radiotherapy.

Clinical Progress: Demonstrated Success in the Community Setting

In October 2025, SCINTIX therapy reached an important clinical milestone when Beverly Hills Cancer Center treated the first patient in a freestanding cancer center. This achievement demonstrated that SCINTIX technology can be successfully implemented outside large hospital systems and scaled to private practice environments.

Dr. Ari Gabayan, Medical Director at Beverly Hills Cancer Center, described autonomous guidance for lung and bone tumors as the “next frontier in precision cancer care.”

Clinical outcomes from the PREMIER registry further support this real-world success. Initial data presented at the 2025 ASTRO Annual Meeting showed 100% local control for lung and bone tumors, with no reported Grade 2 or higher adverse events. These results underscore that SCINTIX therapy can be delivered safely and effectively in community-based settings.

Product Progress: Introducing the RefleXion^® X2 Platform

To support the continued growth of both community and hospital-based programs, RefleXion recently received FDA clearance for its next-generation system, the RefleXion X2 with SCINTIX therapy. To support the continued growth of both community and hospital-based programs, RefleXion recently received FDA clearance for its next-generation system, the RefleXion X2 with SCINTIX therapy, which is designed to enhance tumor detection and visualization.

Key advancements include:

• 20-fold increase in PET sensitivity, significantly amplifying the biological signal for tumor detection

• Fourfold expansion of the imaging field, delivering sharper images with reduced noise

By strengthening the biological signal, the X2 platform has the potential to expand the number of patients eligible for SCINTIX therapy.

Together, accretive reimbursement, proven clinical performance, and next-generation technology are clearing the path for freestanding cancer centers to deliver advanced autonomous radiotherapy—bringing innovative cancer care closer to the communities that need it most.